Source comparison
Mechanism of Action: FAK-eNOS vs FPR2-EGFR
BPC-157 (Body Protection Compound-157, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da) initiates wound healing biology through focal adhesion kinase (FAK) phosphorylation at Tyr-397 in fibroblasts and endothelial cells, independently
This comparison does not assign a generated winner or score.
- BPC-157 (Body Protection Compound-157, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da) initiates wound healing biology through focal adhesion kinase (FAK) phosphorylation at Tyr-397 in fibroblasts and endothelial cells, independently of an identified cell-surface receptor. FAK-pY397 activates downstream: PI3K-Akt-eNOS → nitric oxide (NO) production; VEGFR2 transactivation → ERK1/2-JNK → VEGF-A upregulation and endothelial migration; vinculin and paxillin phosphorylation → focal adhesion assembly → fibroblast lamellipodia and directed migration. The net effect is a co-ordinated pro-angiogenic, pro-fibroblastic response that drives granulation tissue formation, collagen synthesis, and vessel ingrowth — the connective tissue phase of wound repair.
- LL-37’s wound healing entry point is fundamentally different. LL-37 binds formyl peptide receptor 2 (FPR2) on keratinocytes (EC₅₀ ~10–100 nM), activating Gαi-ERK1/2-β-arrestin-mediated keratinocyte migration and proliferation — driving re-epithelialisation, the epidermal component of wound closure. Simultaneously, LL-37 transactivates EGFR (epidermal growth factor receptor) on keratinocytes via metalloprotease-dependent HB-EGF shedding, producing a synergistic proliferative response (+28–34% Ki-67 by EGFR + FPR2 dual activation). LL-37 also recruits neutrophils and monocytes to the wound site via CXCR2 and CXCR4, providing the antimicrobial immune coverage that prevents bacterial colonisation during the vulnerable granulation phase.